EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 14-Aug-2025 09:11 ET (14-Aug-2025 13:11 GMT/UTC)

Moffitt study uncovers a way to boost treatment for aggressive melanoma

H. Lee Moffitt Cancer Center & Research Institute
Peer-Reviewed Publication

A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.

Journal: Cancer Research
Meeting: AACR Annual Meeting 2025

Adding perioperative pembrolizumab to standard of care improves outcomes in patients with newly diagnosed head and neck cancer

American Association for Cancer Research
Reports and Proceedings

Supplementing standard therapy with perioperative PD-1 blockade benefitted patients with untreated, locally advanced head and neck cancer in a phase III clinical trial, according to results presented by Ravindra Uppaluri, MD, at the AACR Annual Meeting 2025.

Meeting: AACR Annual Meeting 2025

Immunotherapy before and after surgery improves outcomes in head and neck cancer

Dana-Farber Cancer Institute
Reports and Proceedings

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.

Immunotherapy improves survival of patients with locally advanced head and neck cancer

WashU Medicine
Reports and Proceedings

An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.

Funder: Merck Sharp & Dohme LLC
Meeting: AACR Annual Meeting 2025

Oral investigational agent zoldonrasib elicits objective responses in patients with KRAS G12D-mutated lung cancer

American Association for Cancer Research
Reports and Proceedings

The KRAS G12D inhibitor zoldonrasib elicited responses in patients with KRAS G12D-mutated non-small cell #LungCancer in a phase I clinical trial, according to results presented by Kathryn C. Arbour, MD, at the AACR Annual Meeting 2025.

Meeting: AACR Annual Meeting 2025

AACR announces 2025 Scientific Achievement Award recipients

American Association for Cancer Research
Grant and Award Announcement

CHICAGO – The American Association for Cancer Research (AACR) will honor the following cancer researchers and physician-scientists during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois.

Meeting: AACR Annual Meeting 2025

AACR announces 2025 Distinguished Public Service Award recipients

American Association for Cancer Research
Grant and Award Announcement

The American Association for Cancer Research (AACR) will honor leaders from government and the advocacy community with 2025 AACR Distinguished Public Service Awards at the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois.

Meeting: AACR Annual Meeting 2025

Richard Pazdur, MD, honored with the 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine

American Association for Cancer Research
Grant and Award Announcement

The 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine will be presented to Richard Pazdur, MD, during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois. Pazdur will accept the award and give remarks during the meeting’s Opening Ceremony on Sunday, April 27, which begins at 7:45 a.m. CT.

Meeting: AACR Annual Meeting 2025

AACR launches its largest-ever grant program to support early-stage and mid-career cancer researchers

American Association for Cancer Research
Grant and Award Announcement

The American Association for Cancer Research (AACR) today announced the launch of the AACR Trailblazer Cancer Research Grant Program during the Opening Ceremony of the AACR Annual Meeting 2025. This bold new grant program will award 15 grants of $1 million each to early-stage and mid-career investigators to support meritorious and promising cancer research.

Meeting: AACR Annual Meeting 2025

Triggers 'cellular storm' for smart tumor elimination

Science China Press
Peer-Reviewed Publication

Novel cancer therapy combining multi-hydroxylated fullerene (MF) nanoparticles and mTOR inhibitors triggers organelle cascade collapse in tumors, disrupting cancer cells' self-repair capacity. By synchronizing the membrane-breaking effect of MF with dual autophagy regulation, this strategy induces lysosomal rupture, mitochondrial dysfunction, and endoplasmic reticulum stress while paralyzing cellular cleanup systems. Animal studies demonstrate potent tumor suppression and high safety, leveraging cancer cells' fragile organelle networks against them. The breakthrough establishes organelle communication disruption as a new anticancer paradigm, pioneering material science-enabled therapies independent of genetic targets.

Journal: Science Bulletin